Premium Company Profile: Endo Pharmaceuticals

Summary

Endo Pharmaceuticals' main focus is to develop and market prescription drugs for pain management. The company's marketed product, Lidoderm, indicated for the relief of pain associated with post-herpetic neuralgia, has been the major contributor to its revenues. Further, the company's acquisition of RxKinetix in 2006 provided an expansion of the company into therapeutic areas.

Scope

• Contains corporate strategy, value chain presence and SWOT Analysis
• Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
• Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals. The company has a portfolio of branded products that includes: Lidoderm, Percocet, Frova, Percodan, Opana, Opana ER and Synera.

The company's lead product candidate EN 3285 Oral Rinse for treating Oral mucositis is currently in Phase 2 clinical trials. In addition, Endo Pharmaceuticals has two licensed products in Phase 3 namely: topical ketoprofen patch and rapinyl used for treating pain associated with soft tissue injuries and cancer, respectively.

Endo Pharmaceuticals derives its revenues from product sales of its proprietary and in-licensed products. The company's total revenues increased at a CAGR of 10.9% during 2002-2006, from $399 million to $909.7 million. This represents an absolute total growth of +$510 million for total revenues.

Reasons to Purchase

• Access all the important information and analysis on the company in a single report
• Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
• Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content